Lilly’s oncology division is sometimes overshadowed by its metabolic medicine and neurology businesses, but cancer drugs were the second biggest contributor to the company’s $25 billion revenue through the first nine months of the year. Long-lived drugs like Alimta and Erbitux still make contributions, but the company is counting on newer drugs like Jaypirca and Retevmo to boost growth.
Both those drugs came via the $8 billion acquisition of Loxo Oncology in 2019, which Lilly undertook to replace revenue as Alimta and Erbitux’s intellectual property protections expired.
